






<https://doi.org/10.1038/s41467-021-26548-6>

OPEN

Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein

Min Thura, Abdul Qader Al-Aidaros , Abhishek Gupta, Cheng Ean Chee, Soo Chin Lee, Kam Man Hui, Jie Li, Yeoh Khay Guan, Wei Peng Yong, Jimmy So, Wee Joo Chng, Chin Hin Ng, Jianbiao Zhou , Ling Zhi Wang, John Shyi Peng Yuen, Henry Sun Sien Ho, Sim Mei Yi , Edmund Chiong, Su Pin Choo, Joanne Ngeow, Matthew Chau Hsien Ng, Clarinda Chua, Eugene Shen Ann Yeo, Iain Bee Huat Tan, Joel Xuan En Sng, Nicholas Yan Zhi Tan, Jean Paul Thiery, Boon Cher Goh & Qi Zeng

Correction to: *Nature Communications* <https://doi.org/10.1038/s41467-019-10127-x>, published online 06 June 2019.

In this article the funding from ‘Open Fund-Individual Research Grant (OF-IRG), National Medical Research Council (NMRC) Singapore with the project ID of NMRC/OFIRG/0053/2017’ was omitted.

Published online: 02 November 2021



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021